Department of Surgery, Erasmus MC, University Medical Centre Rotterdam, GD Rotterdam 3015, the Netherlands.
Department of Surgery, Trinity Translational Medicine Institute, Trinity College Dublin St. James's Hospital, Dublin 8, Dublin, Ireland.
Exp Biol Med (Maywood). 2019 Oct;244(14):1210-1219. doi: 10.1177/1535370219868671. Epub 2019 Aug 7.
Esophageal adenocarcinoma displays a poor prognosis and current treatments are often not curative. Pathological TNM-stage is a prognostic parameter, but a better understanding of the pathophysiology of esophageal adenocarcinoma is needed to better predict survival. Recent work in other malignancies indicated an important role for the regulator microRNA-126 (miR-126) in tumors. The aim of this study was to investigate the function of miR-126 in esophageal adenocarcinoma and to correlate expression of miR-126 with tumor cell behavior and patient survival. Functional assays were performed in esophageal adenocarcinoma cell lines (OE33) by overexpressing or antagonizing miR-126 and assessing cellular processes linked to the hallmarks of cancer. pre-treatment biopsies of 58 patients with esophageal adenocarcinoma who underwent neoadjuvant chemoradiotherapy and surgery were analyzed for miR-126 expression in tumor cells by qRT-PCR and patient survival was analyzed by Kaplan–Meier and Cox regression. In OE33 cancer cells, stable overexpression of miR-126 modest though significantly altered expression of genes related to cell death (MEK1) and DNA repair (POLB and TERF1) was observed. Also the secretion of the angiogenic and pro-inflammatory factors, VEGF, IL-1β, and IL-6 were regulated by miR-126 ( < 0.029). Importantly, miR-126 was found to be a regulator of cell viability in OE33 cells. Overexpressing ( = 0.043) and antagonizing ( = 0.035) miR-126 showed reciprocal effects on tumor cell viability and significantly regulated expression of pro- and anti-apoptotic genes, TP53, and GATA6 ( < 0.031). In patients, high levels of miR-126 expression in pre-treatment tumors were significantly associated with poor survival ( = 0.031). In multivariable analysis, high miR-126 ( = 0.038) together with ypN-stage ( = 0.048) were shown to be independent risk factors for poor survival. In conclusion, high expression of miR-126 in esophageal adenocarcinoma prevents tumor-cell death and is associated with poor patient survival. This study warrants further analysis of miR-126 as biomarker or potential therapeutic target for OAC.
Esophageal adenocarcinoma is a common form of cancer of the esophagus. It has an increasing health impact as it is associated with very poor patient survival. A better understanding of the pathophysiology of this cancer is needed to identify better treatment strategies and to provide a better prognosis for these patients. MicroRNAs have emerged as important molecular regulators of cancer cell viability and proliferation. The aim of our study was to investigate the role of one very well established microRNA, miR-126, in esophageal adenocarcinoma. Our research shows clear experimental evidence that miR-126 controls cell viability of esophageal adenocarcinoma cells. High (over)expression of miR-126 increased the viability of these cells. Our preclinical data were shown to be clinically relevant for this field of oncology. In an independent validation study of esophageal adenocarcinoma biopsies, we confirmed that high miR-126 expression in tumor cells was an independent risk factor for poor patient survival.
探讨 miR-126 在食管腺癌中的功能,并将 miR-126 的表达与肿瘤细胞行为和患者生存相关联。
通过过表达或拮抗 miR-126 并评估与癌症特征相关的细胞过程,在食管腺癌细胞系(OE33)中进行功能测定。对 58 例接受新辅助放化疗和手术的食管腺癌患者的术前活检进行 miR-126 在肿瘤细胞中的表达分析,并通过 Kaplan-Meier 和 Cox 回归分析患者的生存情况。
在 OE33 癌细胞中,观察到 miR-126 稳定过表达后,与细胞死亡(MEK1)和 DNA 修复(POLB 和 TERF1)相关的基因表达发生了适度但显著的改变。miR-126 还调节了血管生成和促炎因子 VEGF、IL-1β 和 IL-6 的分泌(<0.029)。重要的是,miR-126 被发现是 OE33 细胞活力的调节剂。过表达(=0.043)和拮抗(=0.035)miR-126 对肿瘤细胞活力表现出相反的影响,并显著调节促凋亡和抗凋亡基因 TP53 和 GATA6 的表达(<0.031)。在患者中,术前肿瘤中 miR-126 高表达与生存不良显著相关(=0.031)。在多变量分析中,高 miR-126(=0.038)和 ypN 期(=0.048)均被证明是生存不良的独立危险因素。
食管腺癌中 miR-126 的高表达可阻止肿瘤细胞死亡,并与患者生存不良相关。本研究进一步证实 miR-126 可作为 OAC 的生物标志物或潜在治疗靶点。